FL115

DRUG4 trials

Sponsors

Suzhou Forlong Biotechnology Co., Ltd

Conditions

Advanced Solid TumoursLocally Advanced/Metastatic Solid TumorsNon-muscle Invasive Bladder Cancer (NMIBC)

Phase 1

First-in-Human, Phase I, Open-label, Multicenter, Dose Escalation Clinical Study

CompletedNCT06130722

Suzhou Forlong Biotechnology Co., LtdLocally Advanced/Metastatic Solid Tumors

Start: 2023-12-30End: 2025-09-19Updated: 2026-01-07

A Study of Intravesical FL115 Alone or in Combination With BCG in Non-Muscle Invasive Bladder Cancer

RecruitingNCT07122414

Suzhou Forlong Biotechnology Co., LtdNon-muscle Invasive Bladder Cancer (NMIBC)

Start: 2024-08-16End: 2028-10-10Target: 80Updated: 2025-08-14

A Study of FL115 Monotherapy in Unresectable or Metastatic Solid Tumors

Active, not recruitingNCT07131189

Suzhou Forlong Biotechnology Co., LtdLocally Advanced/Metastatic Solid Tumors

Start: 2024-05-30End: 2026-08-10Target: 30Updated: 2026-01-08

A Study of Subcutaneous FL115 Monotherapy in Participants With Advanced Solid Tumors

Not yet recruitingNCT07785193

Suzhou Forlong Biotechnology Co., LtdAdvanced Solid Tumours

Start: 2026-09-01End: 2029-09-01Target: 29Updated: 2026-08-26

Related Papers

Safety, pharmacokinetics (PK), pharmacodynamics (PD), and antitumor activities of FL115, a novel IL-15 superagonist, from the first-in-human study in patients with locally advanced/metastatic solid tumors.

Journal of Clinical Oncology2026-05-27